[{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NP001","moa":"Macrophage","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ Not Applicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NP001","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ Not Applicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"PrimeStreet Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"NP001","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Neuvivo","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Neuvivo \/ PrimeStreet Capital","highestDevelopmentStatusID":"8","companyTruncated":"Neuvivo \/ PrimeStreet Capital"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Chlorite","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Neuvivo \/ Not Applicable"},{"orgOrder":0,"company":"Neuvivo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NP001","moa":"","graph1":null,"graph2":null,"graph3":"Neuvivo","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Neuvivo \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Neuvivo \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Neuvivo

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : NP001 is an HSP90 inhibitor small molecule drug candidate which is currently being evaluated for the treatment of patients with amyotrophic lateral sclerosis.

                          Brand Name : NP001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 16, 2024

                          Lead Product(s) : NP001

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : NP001 is an investigational product (sodium chlorite), which is being investigated in the late-stage clinical trial for the treatment of amyotrophic lateral sclerosis.

                          Brand Name : NP001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 07, 2024

                          Lead Product(s) : Chlorite

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : The financing will be used for the continued development of NP001, a novel regulator of inflammatory macrophages and monocytes, for the treatment of ALS.

                          Brand Name : NP001

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 15, 2023

                          Lead Product(s) : NP001

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : PrimeStreet Capital

                          Deal Size : $11.0 million

                          Deal Type : Financing

                          blank

                          04

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : NP001, is a small molecule which, through a series of biochemical interactions in the body, is converted to a compound that can transform inflammatory macrophages (M1) to the non-inflammatory, wound healing state (M2), with the goal of stopping damage to...

                          Brand Name : NP001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 01, 2022

                          Lead Product(s) : NP001

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          SupplySide West 2024
                          Not Confirmed
                          SupplySide West 2024
                          Not Confirmed

                          Details : NP001 has been shown to be effective and safe in clinical trials. Published data show a 38% slowing of disease progression as measured by ALSFRS-R score and importantly, a 51% slowing of the decline in lung function compared to placebo.

                          Brand Name : NP001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 11, 2022

                          Lead Product(s) : NP001

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank